What question did this study set out to answer?

To compare the protective efficacy of synthetic mRNA and self-amplifying RNA vaccine platforms expressing influenza hemagglutinin across different dose levels.

December 6, 2017Molecular TherapyOpen Access

Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses

View Full Paper

Ask AI

Bookmark

To compare the protective efficacy of synthetic mRNA and self-amplifying RNA vaccine platforms expressing influenza hemagglutinin across different dose levels.
Compared protection conferred by synthetic mRNA versus virally derived self-amplifying RNA (sa-RNA) expressing influenza virus hemagglutinin in animal challenge models.
Evaluated monovalent sa-RNA vaccines targeting hemagglutinin from influenza strains H1N1, H3N2 (X31), and B (Massachusetts).
Tested a trivalent sa-RNA formulation against sequential challenge infections with both H1N1 and H3N2 viruses.
Immunization with 1.25 μg of sa-RNA provided equivalent protective efficacy against influenza compared to 80 μg of synthetic mRNA, achieving a 64-fold dose reduction.
Monovalent sa-RNA vaccines encoding hemagglutinin from H1N1, H3N2 (X31), and B (Massachusetts) each protected fully against homologous viral challenge.
A combined trivalent sa-RNA formulation conferred robust protection against sequential challenges with H1N1 and H3N2 strains.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Comparative preclinical evaluation demonstrates equivalent influenza protection with 64-fold lower doses of self-amplifying RNA versus mRNA, indicating substantial dose-sparing potential.

Cite This Study

Vogel et al. (2017) studied this question.

synapsesocial.com/papers/69d81216617ce96c42ae2dc6 https://doi.org/10.1016/j.ymthe.2017.11.017

View Full Paper

Ask AI

Bookmark

Implication

Comparative preclinical evaluation demonstrates equivalent influenza protection with 64-fold lower doses of self-amplifying RNA versus mRNA, indicating substantial dose-sparing potential.

Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses

Key Points

Discussion

Implication

Cite This Study

Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading